

Prof. Dr. Heinz H. Coenen
(*19. July 1949)

Institute of Neuroscience and Medicine, INM-5:
Nuclear Chemistry, Research Centre Jülich, Germany
Tel: +49 2461 61-4141
Email: h.h.coenen@fz-juelich.de
and
Head of Division of Nuclear Chemistry, Department
of Chemistry, University of Cologne, Germany
Tel: +49 221 470-3219



Curriculum vitae

1975 Master's Diploma, University of Cologne
1979 PhD, University of Cologne
1979-1981 PostDoc, Research Center Jülich
1981-1982 Visiting assistant professor, George Washington University, Washington, DC, USA
1982-1985 Staff member at Institute of Nuclear Chemistry, Research Centre Jülich
1985-1991 Head of the Radiopharmaceutical Chemistry Group at the Institute of Nuclear Chemistry, FZJ
1990 Habilitation, University of Cologne
1991-1996 Assoc. Professor of Nuclear Chemistry and Radiopharmacy, University of Essen
since 1996 Full Professor of Nuclear Chemistry, University of Cologne
since 1996 Director of Institute of Neuroscience and Medicine, INM-5: Nuclear Chemistry at FZJ

Activities in the scientific community, awards

Editorial board member of journals:
1985 - *Nuclear Medicine and Biology*
1999 - *Journal Labelled Compounds and Radiopharmaceuticals*
1988-1998 Board Member of Radiopharmaceutical Committee of DGN
1994-2002 Board Member of Nuclear Chemistry Section of GDCh
since 1999 Vice Chairman of Radiopharmacy Section of DPhG
2000-2005 Vice Chairman of the EU COST action B12
since 2005 Member of PSI-Advisory-Board (PAB) of Paul-Scherrer-Institute, Villigen, CH
2005-2011 President of the Society of Radiopharmaceutical Sciences (SRS)
1990 Mallinckrodt-Promotion Award, German Society of Nuclear Medicine (DGN)
2013 President's Award, Society of Radiopharmaceutical Sciences (SRS)

Research fields

My main research interests comprise all aspects of radiopharmaceutical sciences, from nuclide production to translation of radioindicators into radiodiagnostics applied in man with in vivo imaging methods. Bases are measurements of nuclear data and development of medically relevant radionuclides at cyclotrons. Labelling methods using short-lived isotopes, such as fluorine-18, bromine-75,76, iodine-120,123,124, as well as carbon-11 and selenium-73,75 are a special focus. The "no-carrier-added" production of tracers in subnano-molar amounts concentrates on biomolecules, such as amino acids, or builds on lead structures of pharmaceuticals binding to receptors, transporters or enzymes. The development of preclinical evaluation methods for the no-carrier-added, short-lived radiotracers represents a further topic. This comprises in vitro and in vivo studies on biodistribution and metabolism with the help of modern radioanalytical methods. Those find also application in the pharmaceutical quality control of radiodiagnostics produced for routine human application. In cooperation with different institutes of medicine, the new developed radiotracers and -ligands are examined by emission-tomography imaging methods (SPECT or PET) with respect to their suitability for translation into in vivo diagnostic agents, or in collaboration with pharmaceutical industry used for evaluation of research drugs.

Selected publications

PUBLICATIONS FROM 1985 TO 2015

1. Cornelius J, Stoffels G, Filss C, Galldiks N, Sloty P, Kamp M, et al. Uptake and tracer kinetics of O-(2-F-18-fluoroethyl)-L-tyrosine in meningiomas: preliminary results. *European Journal of Nuclear Medicine and Molecular Imaging*. 2015;42(3):459-67.
2. Dunkl V, Cleff C, Stoffels G, Judov N, Sarikaya-Seiwert S, Law I, et al. The Usefulness of Dynamic O-(2-F-18-Fluoroethyl)-L-Tyrosine PET in the Clinical Evaluation of Brain Tumors in Children and Adolescents. *Journal of Nuclear Medicine*. 2015;56(1):88-92.
3. Kugler F, Ermert J, Kaufholz P, Coenen H. 4-[F-18]Fluorophenylpiperazines by Improved Hartwig-Buchwald N-Arylation of 4-[F-18]fluoroiodobenzene, Formed via Hypervalent lambda(3)-Iodane Precursors: Application to Build-Up of the Dopamine D-4 Ligand [F-18]FAUC 316. *Molecules*. 2015;20(1):470-86.
4. Olma S, Ermert J, Sihver W, Coenen H. Synthesis and First Evaluation of [F-18]Fluorocyano- and [F-18]Fluoronitro-quinoxalinedione as Putative AMPA Receptor Antagonists. *Medicinal Chemistry*. 2015;11(1):13-20.
5. Buchholz M, Spahn I, Coenen H. Cross section measurements of proton and deuteron induced reactions on natural europium and yields of SPECT-relevant radioisotopes of gadolinium. *Applied Radiation and Isotopes*. 2014;91:8-16.
6. Cardinale J, Ermert J, Humpert S, Coenen H. Iodonium ylides for one-step, no-carrier-added radiofluorination of electron rich arenes, exemplified with 4-([F-18] fluorophenoxy)-phenylmethyl) piperidine NET and SERT ligands. *Rsc Advances*. 2014;4(33):17293-9.
7. Coenen H, Kuhn S, Spahn I. Development of the non-standard PET radionuclides Sc-43, Sc-44g and Ti-45. *Nuclear Medicine and Biology*. 2014;41(7):647-8.
8. Filss C, Galldiks N, Stoffels G, Sabel M, Wittsack H, Turowski B, et al. Comparison of F-18-FET PET and Perfusion-Weighted MR Imaging: A PET/MR Imaging Hybrid Study in Patients with Brain Tumors. *Journal of Nuclear Medicine*. 2014;55(4):540-5.
9. Filss C, Stoffels G, Galldiks N, Sabel M, Wittsack H, Coenen H, et al. Histogram analysis reveals a better delineation of tumor volume from background in F-18-FET PET compared to CBV maps in a hybrid PET-MR studie in gliomas. *Nuclear Instruments & Methods in Physics Research Section a-Accelerators Spectrometers Detectors and Associated Equipment*. 2014;734:175-8.
10. Kugler F, Roehrens D, Stumpf M, Drerup C, Ermert J, Hamacher K, et al. Optimizing the transfer of [F-18]fluoride from aqueous to organic solvents by electrodeposition using carbon electrodes. *Applied Radiation and Isotopes*. 2014;91:1-7.
11. Qaim S, Sudar S, Scholten B, Koning A, Coenen H. Evaluation of excitation functions of Mo-100(p,d+pn)Mo-99 and Mo-100 (p,2n)Tc-99m reactions: Estimation of long-lived Tc-impurity and its implication on the specific activity of cyclotron-produced Tc-99m. *Applied Radiation and Isotopes*. 2014;85:101-13.

12. Shah N, Herzog H, Weirich C, Tellmann L, Kaffanke J, Caldeira L, et al. Effects of Magnetic Fields of up to 9.4 T on Resolution and Contrast of PET Images as Measured with an MR-BrainPET. *Plos One*. 2014; 9(4).
13. Striepens N, Matusch A, Kendrick K, Mihov Y, Elmenhorst D, Becker B, et al. Oxytocin enhances attractiveness of unfamiliar female faces independent of the dopamine reward system. *Psychoneuroendocrinology*. 2014;39:74-87.
14. Zhang K, Herzog H, Mauler J, Filss C, Okell T, Kops E, et al. Comparison of cerebral blood flow acquired by simultaneous [O-15]water positron emission tomography and arterial spin labeling magnetic resonance imaging. *Journal of Cerebral Blood Flow and Metabolism*. 2014;34(8):1373-80.
15. Zhang K, Langen K, Neuner I, Stoffels G, Filss C, Galldiks N, et al. Relationship of regional cerebral blood flow and kinetic behaviour of O-(2-F-18-fluoroethyl)-L-tyrosine uptake in cerebral gliomas. *Nuclear Medicine Communications*. 2014;35(3):245-51.
16. Buchholz M, Spahn I, Scholten B, Coenen H. Cross-section measurements for the formation of manganese-52 and its isolation with a non-hazardous eluent. *Radiochimica Acta*. 2013;101(8):491-9.
17. Ermert J, Coenen H. Methods for 11C-and 18F-labelling of amino acids and derivatives for positron emission tomography imaging. *Journal of Labelled Compounds & Radiopharmaceuticals*. 2013;56(3-4):225-36.
18. Galldiks N, Rapp M, Stoffels G, Fink G, Shah N, Coenen H, et al. Response assessment of bevacizumab in patients with recurrent malignant glioma using [F-18]Fluoroethyl-L-tyrosine PET in comparison to MRI. *European Journal of Nuclear Medicine and Molecular Imaging*. 2013;40(1):22-33.
19. Galldiks N, Stoffels G, Ruge M, Rapp M, Sabel M, Reifenberger G, et al. Role of O-(2-F-18-Fluoroethyl)-L-Tyrosine PET as a Diagnostic Tool for Detection of Malignant Progression in Patients with Low-Grade Glioma. *Journal of Nuclear Medicine*. 2013;54(12):2046-54.
20. Geisler S, Willuweit A, Schroeter M, Zilles K, Hamacher K, Galldiks N, et al. Detection of remote neuronal reactions in the Thalamus and Hippocampus induced by rat glioma using the PET tracer cis-4-[F-18]fluoro-D-proline. *Journal of Cerebral Blood Flow and Metabolism*. 2013;33(5):724-31.
21. Helfer A, Ermert J, Coenen H. Ebselen, first radiotracer labelled with the positron emitter selenium-73. *Journal of Labelled Compounds & Radiopharmaceuticals*. 2013;56:S221-S.
22. Helfer A, Melean J, Ermert J, Infantino A, Coenen H. Bis(4-benzyloxyphenyl)iodonium salts as effective precursors for the no-carrier-added radiosynthesis of 4-[F-18]fluorophenol. *Applied Radiation and Isotopes*. 2013;82:264-7.
23. Kranert T, Menzel C, Bartenstein P, Brust P, Coenen H, Krause B, et al. Hirnperfusions-SPECT with 99mTc-labelled Radiopharmaceuticals DGN-Guidance (S1 Guideline). *Nuklearmedizin-Nuclear Medicine*. 2013;52(5):157-62.
24. Kugler F, Ermert J, Coenen H. Labeling of benzodioxin piperazines with fluorine-18 as prospective radioligands for selective imaging of dopamine D-4 receptors. *Journal of Labelled Compounds & Radiopharmaceuticals*. 2013;56(12):609-18.

25. Piroth M, Liebenstund S, Galldiks N, Stoffels G, Shah N, Eble M, et al. Monitoring of Radiochemotherapy in Patients with Glioblastoma Using O-(2-[F-18]Fluoroethyl)-L-Tyrosine Positron Emission Tomography: Is Dynamic Imaging Helpful? *Molecular Imaging*. 2013;12(6).
26. Piroth M, Prasath J, Willuweit A, Stoffels G, Sellhaus B, van Osterhout A, et al. Uptake of O-(2-[F-18]fluoroethyl)-L-tyrosine in reactive astrocytosis in the vicinity of cerebral gliomas. *Nuclear Medicine and Biology*. 2013;40(6):795-800.
27. Rapp M, Heinzl A, Galldiks N, Stoffels G, Felsberg J, Ewelt C, et al. Diagnostic Performance of F-18-FET PET in Newly Diagnosed Cerebral Lesions Suggestive of Glioma. *Journal of Nuclear Medicine*. 2013;54(2):229-35.
28. Ross T, Sihver W, Ermert J, Coenen H. Synthesis and preliminary pharmacological evaluation of a new putative radioiodinated AMPA receptor ligand for molecular imaging. *Radiochimica Acta*. 2013;101(9):571-5.
29. Cardinale J, Ermert J, Coenen H. Convenient preparation of (4-iodophenyl)aryliodonium salts. *Tetrahedron*. 2012;68(22):4112-6.
30. Cardinale J, Ermert J, Kugler F, Helfer A, Brandt M, Coenen H. Carrier-effect on palladium-catalyzed, nucleophilic 18F-fluorination of aryl triflates. *Journal of Labelled Compounds & Radiopharmaceuticals*. 2012;55(12):450-3.
31. Galldiks N, Langen K, Holy R, Pinkawa M, Stoffels G, Nolte K, et al. Assessment of Treatment Response in Patients with Glioblastoma Using O-(2-F-18-Fluoroethyl)-L-Tyrosine PET in Comparison to MRI. *Journal of Nuclear Medicine*. 2012;53(7):1048-57.
32. Galldiks N, Stoffels G, Filss C, Piroth M, Sabel M, Ruge M, et al. Role of O-(2-F-18-Fluoroethyl)-L-Tyrosine PET for Differentiation of Local Recurrent Brain Metastasis from Radiation Necrosis. *Journal of Nuclear Medicine*. 2012;53(9):1367-74.
33. Piroth M, Pinkawa M, Holy R, Klotz J, Schaar S, Stoffels G, et al. Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas Results of a prospective phase II study. *Strahlentherapie Und Onkologie*. 2012;188(4):334-9.
34. Shehata M, Scholten B, Spahn I, Coenen H, Qaim S. Radiochemical separation of Br-76, Br-77 and Ga-66, Ga-67 from irradiated ZnSe targets using anion-exchange chromatography. *Radiochimica Acta*. 2012;100(10):785-92.
35. Al-Abyad M, Spahn I, Scholten B, Spellerberg S, Qaim S, Coenen H, et al. Cross Section Measurements of Proton Induced Reactions on Mn-55 and Comparison of Experimental Results with Different Nuclear Model Calculations. *Journal of the Korean Physical Society*. 2011;59(2):1888-91.
36. Floeth F, Sabel M, Ewelt C, Stummer W, Felsberg J, Reifenberger G, et al. Comparison of F-18-FET PET and 5-ALA fluorescence in cerebral gliomas. *European Journal of Nuclear Medicine and Molecular Imaging*. 2011;38(4):731-41.
37. Herzog H, Langen K, Weirich C, Kops E, Kaffanke J, Tellmann L, et al. High resolution BrainPET combined with simultaneous MRI. *Nuklearmedizin-Nuclear Medicine*. 2011;50(2):74-82.

38. Kugler F, Sihver W, Ermert J, Hubner H, Gmeiner P, Prante O, et al. Evaluation of F-18-Labeled Benzodioxine Piperazine-Based Dopamine D-4 Receptor Ligands: Lipophilicity as a Determinate of Nonspecific Binding. *Journal of Medicinal Chemistry*. 2011;54(24):8343-52.
39. Langen K, Bartenstein P, Boecker H, Brust P, Coenen H, Drzezga A, et al. PET and SPECT Studies of Brian Tumors with Radiolabeled Amino Acids. *Nuklearmedizin-Nuclear Medicine*. 2011;50(4):167-73.
40. Melean J, Ermert J, Coenen H. Enantiospecific synthesis of 2-[F-18]fluoro-L-phenylalanine and 2-[F-18]fluoro-L-tyrosine by isotopic exchange. *Organic & Biomolecular Chemistry*. 2011;9(3):765-9.
41. Piroth M, Holy R, Pinkawa M, Stoffels G, Kaiser H, Galldiks N, et al. Prognostic impact of postoperative, pre-irradiation F-18-fluoroethyl-L-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. *Radiotherapy and Oncology*. 2011;99(2):218-24.
42. Piroth M, Pinkawa M, Holy R, Klotz J, Nussen S, Stoffels G, et al. PROGNOSTIC VALUE OF EARLY [(18)F]FLUOROETHYLTYROSINE POSITRON EMISSION TOMOGRAPHY AFTER RADIOCHEMOTHERAPY IN GLIOBLASTOMA MULTIFORME. *International Journal of Radiation Oncology Biology Physics*. 2011;80(1):176-84.
43. Piroth M, Pinkawa M, Holy R, Klotz J, Schaar S, Stoffels G, et al. Integrated Boost IMRT (IMRT-IB) with FET-PET-adapted local Dose Escalation in Glioblastoma - Results of a prospective Phase II Study. *Strahlentherapie Und Onkologie*. 2011;187:51-2.
44. Piroth M, Pinkawa M, Holy R, Klotz J, Schaar S, Stoffels G, et al. Recurrence Patterns after FET-PET-adapted Radiochemotherapy for Glioblastoma - a prospective Analysis. *Strahlentherapie Und Onkologie*. 2011;187:52-3.
45. Ross T, Ermert J, Coenen H. Synthesis of No-Carrier-Added 4-[F-18]Fluorophenol from 4-Benzyloxyphenyl-(2-thienyl)iodonium Bromide. *Molecules*. 2011;16(9):7621-6.
46. Shehata M, Scholten B, Spahn I, Coenen H, Qaim S. Separation of radioarsenic from irradiated germanium oxide targets for the production of As-71 and As-72. *Journal of Radioanalytical and Nuclear Chemistry*. 2011;287(2):435-42.
47. Shehata M, Scholten B, Spahn I, Qaim S, Coenen H. Radiochemical studies relevant to the separation of Ga-68 and Ge-68. *Journal of Radioanalytical and Nuclear Chemistry*. 2011;288(3):887-93.
48. Skakun Y, Utenkov S, Dovbnya A, Qaim S, Coenen H. Half-lives of the Isomeric States Rh-102m,Rh-g. *Journal of the Korean Physical Society*. 2011;59(2):1487-90.
49. Spahn I, Shehata M, Spellerberg S, Scholten B, Coenen H, Qaim S, et al. Investigation of Production Possibilities of Radiobromines for Diagnostic and Therapeutic Applications. *Journal of the Korean Physical Society*. 2011;59(2):1983-6.
50. Uddin M, Hermanne A, Scholten B, Spellerberg S, Coenen H, Qaim S. Small scale production of high purity Pt-193m by the Os-192(alpha, 3n)-process. *Radiochimica Acta*. 2011;99(3):131-5.
51. Uddin M, Hermanne A, Sudar S, Aslam M, Scholten B, Coenen H, et al. Excitation functions of alpha-

particle induced reactions on enriched Sb-123 and Sb-nat for production of I-124. *Applied Radiation and Isotopes*. 2011;69(4):699-704.

52. Coenen H, Elsinga P, Iwata R, Kilbourn M, Pillai M, Rajan M, et al. Fluorine-18 radiopharmaceuticals beyond [F-18]FDG for use in oncology and neurosciences. *Nuclear Medicine and Biology*. 2010;37(7):727-40.
53. Melean J, Ermert J, Coenen H. Efficient synthesis of fluorobenzoyloimidazolidinone derivatives: precursors for the radiosynthesis of [F-18] fluorophenylamino acids. *Tetrahedron*. 2010;66(52):9996-10001.
54. Muhlhausen U, Sihver W, Ermert J, Coenen H. Synthesis, radiofluorination and first evaluation of [F-18]fluorophenylsulfonyl- and [F-18]fluorophenylsulfinyl-piperidines as serotonin 5-HT_{2A} receptor antagonists for PET. *Nuclear Medicine and Biology*. 2010;37(5):605-14.
55. Qaim S, Ketterer K, Shubin Y, Sudar S, Coenen H. Excitation functions of nuclear reactions leading to the soft-radiation emitting radionuclides Ca-45, V-49 and Tl-204 in beam collimator materials used in proton therapy. *Radiochimica Acta*. 2010;98(8):447-57.
56. Salber D, Stoffels G, Oros-Peusquens A, Shah N, Reifemberger G, Hamacher K, et al. Comparison of O-(2-(18)F-Fluoroethyl)-L-Tyrosine and L-(3)H-Methionine Uptake in Cerebral Hematomas. *Journal of Nuclear Medicine*. 2010;51(5):790-7.
57. Spahn I, Steyn G, Vermeulen C, Kovacs Z, Szelecsenyi F, Shehata M, et al. New cross section measurements for the production of the Auger electron emitters Br-77 and Br-80m. *Radiochimica Acta*. 2010;98(12):749-55.
58. Uddin M, Scholten B, Hermanne A, Sudar S, Coenen H, Qaim S. Radiochemical determination of cross sections of alpha-particle induced reactions on Os-192 for the production of the therapeutic radionuclide Pt-193m. *Applied Radiation and Isotopes*. 2010;68(10):2001-6.
59. Coenen H. A letter from the SRS President. *Nuclear Medicine and Biology*. 2009;36(2).
60. Coenen H. A letter from the SRS President. *Nuclear Medicine and Biology*. 2009;36(4).
61. Jahnke S, Menzel M, van Dusschoten D, Roeb G, Buhler J, Minwuyet S, et al. Combined MRI-PET dissects dynamic changes in plant structures and functions. *Plant Journal*. 2009;59(4):634-44.
62. Ketterer K, Coenen H, Qaim S. Quantification of radiation dose from short-lived positron emitters formed in human tissue under proton therapy conditions. *Radiation Physics and Chemistry*. 2009;78(6):380-5.
63. Muhlhausen U, Ermert J, Coenen H. Synthesis, labelling and first evaluation of [F-18]R91150 as a serotonin 5-HT_{2A} receptor antagonist for PET. *Journal of Labelled Compounds & Radiopharmaceuticals*. 2009;52(1-2):13-22.
64. Muhlhausen U, Ermert J, Herth M, Coenen H. Synthesis, radiofluorination and first evaluation of (+/-)-[F-18]MDL 100907 as serotonin 5-HT_{2A} receptor antagonist for PET. *Journal of Labelled Compounds & Radiopharmaceuticals*. 2009;52(1-2):6-12.

65. Pauleit D, Stoffels G, Bachofner A, Floeth F, Sabel M, Herzog H, et al. Comparison of F-18-FET and F-18-FDG PET in brain tumors. *Nuclear Medicine and Biology*. 2009;36(7):779-87.
66. Qaim S, Hilgers K, Sudar S, Coenen H. Excitation function of the Os-192(He-3,4n)-reaction for production of Pt-191. *Applied Radiation and Isotopes*. 2009;67(6):1074-7.
67. Spahn I, Steyn G, Vermeulen C, Kovacs Z, Szelecsenyi F, Coenen H, et al. New cross section measurements for production of the positron emitters Br-75 and Br-76 via intermediate energy proton induced reactions. *Radiochimica Acta*. 2009;97(10):535-41.
68. Thiele F, Ehmer J, Piroth M, Eble M, Coenen H, Kaiser H, et al. The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma. *Physics in Medicine and Biology*. 2009;54(18):5525-39.
69. Wagner F, Ermert J, Coenen H. Three-Step, "One-Pot" Radiosynthesis of 6-Fluoro-3,4-Dihydroxy-L-Phenylalanine by Isotopic Exchange. *Journal of Nuclear Medicine*. 2009;50(10):1724-9.
70. Boy C, Meyer P, Kircheis G, Holschbach M, Herzog H, Elmenhorst D, et al. Cerebral A(1) adenosine receptors (A(1)AR) in liver cirrhosis. *European Journal of Nuclear Medicine and Molecular Imaging*. 2008;35(3):589-97.
71. Coenen H. A letter from the SRS president. *Nuclear Medicine and Biology*. 2008;35(3).
72. Ermert J, Stusgen S, Lang M, Roden W, Coenen H. High molar activity of [C-11]TCH346 via [C-11]methyl triflate using the "wet" [C-11]CO₂ reduction method. *Applied Radiation and Isotopes*. 2008;66(5):619-24.
73. Herzog H, Tellmann L, Scholten B, Coenen H, Qaim S. PET imaging problems with the non-standard positron emitters Yttrium-86 and Iodine-124. *Quarterly Journal of Nuclear Medicine and Molecular Imaging*. 2008;52(2):159-65.
74. Hilgers K, Coenen H, Qaim S. Production of the therapeutic radionuclides Pt-193m and Pt-195m with high specific activity via alpha-particle-induced reactions on Os-192. *Applied Radiation and Isotopes*. 2008;66(4):545-51.
75. Schott B, Minuzzi L, Krebs R, Elmenhorst D, Lang M, Winz O, et al. Mesolimbic Functional Magnetic Resonance Imaging Activations during Reward Anticipation Correlate with Reward-Related Ventral Striatal Dopamine Release. *Journal of Neuroscience*. 2008;28(52):14311-9.
76. Stoffels G, Pauleit D, Haas R, Kobbe G, Salber D, Hamacher K, et al. cis-4-[(18F)-Fluoro-L-proline fails to detect peripheral tumors in humans. *Nuclear Medicine and Biology*. 2008;35(8):895-900.
77. Verbruggen A, Coenen H, Deverre J, Guilloteau D, Langstrom B, Salvadori P, et al. Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. *European Journal of Nuclear Medicine and Molecular Imaging*. 2008;35(11):2144-51.
78. Waerzeggers Y, Klein M, Miletic H, Himmelreich U, Li H, Monfared P, et al. Multimodal imaging of neural progenitor cell fate in rodents. *Molecular Imaging*. 2008;7(2):77-91.

79. Drewes B, Sihver W, Willbold S, Olsson R, Coenen H. New 2 alpha-tropane amides as potential PET ligands for the dopamine transporter. *Nuclear Medicine and Biology*. 2007;34(5):531-9.
80. Elmenhorst D, Meyer P, Winz O, Matusch A, Ermert J, Coenen H, et al. Sleep deprivation increases A(1) adenosine receptor binding in the human brain: A positron emission tomography study. *Journal of Neuroscience*. 2007;27(9):2410-5.
81. Ermert J, Ludwig T, Gail R, Coenen H. [F-18]fluorophenyl organometallics as intermediates of no-carrier-added F-18-fluoroarylation reactions. *Journal of Organometallic Chemistry*. 2007;692(19):4084-92.
82. Floeth F, Pauleit D, Sabel M, Stoffels G, Reifenberger G, Riemenschneider M, et al. Prognostic value of O-(2-F-18-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. *Journal of Nuclear Medicine*. 2007;48(4):519-27.
83. Kandil S, Scholten B, Saleh Z, Youssef A, Qaim S, Coenen H. A comparative study on the separation of radiozirconium via ion-exchange and solvent extraction techniques, with particular reference to the production of Zr-88 and Zr-89 in proton induced reactions on yttrium. *Journal of Radioanalytical and Nuclear Chemistry*. 2007;274(1):45-52.
84. Kandil S, Spahn I, Scholten B, Saleh Z, Saad S, Coenen H, et al. Excitation functions of (alpha,xn) reactions on Rb-nat and Sr-nat from threshold up to 26 MeV: Possibility of production of Y-87, Y-88 and Zr-89. *Applied Radiation and Isotopes*. 2007;65(5):561-8.
85. Kronenberg U, Drewes B, Sihver W, Coenen H. N-2-(4-N-(4-[F-18]Fluorobenzamido)phenyl)-propyl-2-propanesulphonamide: synthesis and radiofluorination of a putative AMPA receptor ligand. *Journal of Labelled Compounds & Radiopharmaceuticals*. 2007;50(13-14):1169-75.
86. Langen K, Floeth F, Stoffels G, Hamacher K, Coenen H, Pauleit D. Improved diagnostics of cerebral gliomas using FET PET. *Zeitschrift Fur Medizinische Physik*. 2007;17(4):237-41.
87. Langen K, Salber D, Hamacher K, Stoffels G, Reifenberger G, Pauleit D, et al. Detection of secondary thalamic degeneration after cortical infarction using cis-4-F-18-Fluoro-D-proline. *Journal of Nuclear Medicine*. 2007;48(9):1482-91.
88. Prante O, Hamacher K, Coenen H. Chemoenzymatic n.c.a synthesis of the coenzyme UDP-2-deoxy-2-(F-18)fluoro-alpha-D-glucopyranose as substrate of glycosyltransferases. *Journal of Labelled Compounds & Radiopharmaceuticals*. 2007;50(1-2):55-63.
89. Qaim S, Bisinger T, Hilgers K, Nayak D, Coenen H. Positron emission intensities in the decay of Cu-64, Br-76 and I-124. *Radiochimica Acta*. 2007;95(2):67-73.
90. Qaim S, Spahn I, Kandil S, Coenen H. Nuclear data for production of Y-88, Nd-140, Sm-153 and Yb-169 via novel routes. *Radiochimica Acta*. 2007;95(6):313-7.
91. Qaim S, Steyn G, Spahn I, Spellerberg S, van der Walt T, Coenen H. Yield and purity of Sr-82 produced via the Rb-nat(p,xn)Sr-82 process. *Applied Radiation and Isotopes*. 2007;65(2):247-52.
92. Ross T, Ermert J, Hocke C, Coenen H. Nucleophilic F-18-Fluorination of heteroaromatic iodonium salts

with no-carrier-added [F-18]Fluoride. *Journal of the American Chemical Society*. 2007;129(25):8018-25.

93. Salber D, Stoffels G, Pauleit D, Oros-Peusquens A, Shah N, Klauth P, et al. Differential uptake of O-(2-F-18-fluoroethyl)-L-tyrosine, L-H-3-methionine, and H-3-deoxyglucose in brain abscesses. *Journal of Nuclear Medicine*. 2007;48(12):2056-62.
94. Sihver W, Drewes B, Schulze A, Olsson R, Coenen H. Evaluation of novel tropane analogues in comparison with the binding characteristics of [F-18]FP-CIT and [I-131]beta-CIT. *Nuclear Medicine and Biology*. 2007;34(2):211-9.
95. Spahn I, Steyn G, Nortier F, Coenen H, Qaim S. Excitation functions of Ge-nat(p,xn)(71,72,73,74) As reactions up to 100 MeV with a focus on the production of As-72 for medical and As-73 for environmental studies. *Applied Radiation and Isotopes*. 2007;65(9):1057-64.
96. Al-Abyad M, Spahn I, Sudar S, Morsy M, Comsan M, Csikai J, et al. Nuclear data for production of the therapeutic radionuclides P-32, Cu-64 Cu-67, Sr-89, Y-90 and Sm-153 via the (n,p) reaction: Evaluation of excitation function and its validation via integral cross-section measurement using a 14MeV d(Be) neutron source. *Applied Radiation and Isotopes*. 2006;64(6):717-24.
97. Bier D, Holschbach M, Wutz W, Olsson R, Coenen H. Metabolism of the A(1) adenosine receptor positron emission tomography ligand [(18)F]8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine ([18F]CPFPX) in rodents and humans. *Drug Metabolism and Disposition*. 2006;34(4):570-6.
98. Hamacher K, Coenen H. No-carrier-added nucleophilic F-18-labelling in an electrochemical cell exemplified by the routine production of [F-18]altanserin. *Applied Radiation and Isotopes*. 2006;64(9):989-94.
99. Hassan K, Qaim S, Saleh Z, Coenen H. Alpha-particle induced reactions on (nat)sb and (121)sb with particular reference to the production of the medically interesting radionuclide (124)i. *Applied Radiation and Isotopes*. 2006;64(1):101-9.
100. Hassan K, Qaim S, Saleh Z, Coenen H. He-3-particle-induced reactions on Sb-nat for production of I-124. *Applied Radiation and Isotopes*. 2006;64(4):409-13.
101. Herzog H, Qaim S, Tellmann L, Spellerberg S, Kruecker D, Coenen H. Assessment of the short-lived non-pure positron-emitting nuclide I-120 for PET imaging. *European Journal of Nuclear Medicine and Molecular Imaging*. 2006;33(11):1249-57.
102. Holschbach M, Bier D, Stusgen S, Wutz W, Sihver W, Coenen H, et al. Synthesis and evaluation of 7-amino-2-(2(3)-furyl)-5-phenylethylamino-oxazolo[5,4-d]pyrimidines as potential A(2A) adenosine receptor antagonists for positron emission tomography (PET). *European Journal of Medicinal Chemistry*. 2006;41(1):7-15.
103. Langen K, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D, et al. O-(2-[(18)F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. *Nuclear Medicine and Biology*. 2006;33(3):287-94.
104. Olma S, Ermert J, Coenen H. 4-[F-18]fluorophenyl ureas via carbamate-4-nitrophenyl esters and 4-[F-18]fluoroaniline. *Journal of Labelled Compounds & Radiopharmaceuticals*. 2006;49(12):1037-50.

105. Pauleit D, Zimmermann A, Stoffels G, Bauer D, Risse J, Fluss M, et al. F-18-FET PET compared with F-18-FDG PET and CT in patients with head and neck cancer. *Journal of Nuclear Medicine*. 2006;47(2):256-61.
106. Piroth M, Boy C, Gagel B, Schmachtenberg A, Pinkawa M, Langen K, et al. Molecular imaging in the irradiation planning of highly malignant gliomas - PTV comparison of a CT/MRT-based with an O-(2-F-18-fluorethyl)-L-tyrosine PET (FET-PET)-based planning. *Strahlentherapie Und Onkologie*. 2006;182:55-6.
107. Salber D, Stoffels G, Pauleit D, Reifenberger G, Sabel M, Shah N, et al. Differential uptake of [F-18]FET and [H-3]L-methionine in focal cortical ischemia. *Nuclear Medicine and Biology*. 2006;33(8):1029-35.
108. Zimny M, Gagel B, DiMartino E, Hamacher K, Coenen H, Westhofen M, et al. FDG - a marker of tumour hypoxia? A comparison with [F-18] fluoromisonidazole and pO(2)-polarography in metastatic head and neck cancer. *European Journal of Nuclear Medicine and Molecular Imaging*. 2006;33(12):1426-31.
109. Bauer A, Langen K, Bidmon H, Holschbach M, Weber S, Olsson R, et al. F-18-CPFPX PET identifies changes in cerebral A(1) adenosine receptor density caused by glioma invasion. *Journal of Nuclear Medicine*. 2005;46(3):450-4.
110. Bauer D, Hamacher K, Broer S, Pauleit D, Palm C, Zilles K, et al. Preferred stereoselective brain uptake of D-serine - a modulator of glutamatergic neurotransmission. *Nuclear Medicine and Biology*. 2005;32(8):793-7.
111. Hilgers K, Shubin Y, Coenen H, Qaim S. Experimental measurements and nuclear model calculations on the excitation functions of Ce-nat(He-3,xn) and Pr-141(p,xn) reactions with special reference to production of the therapeutic radionuclide Nd-140. *Radiochimica Acta*. 2005;93(9-10):553-60.
112. Hurlmann R, Boy C, Meyer P, Scherk H, Wagner M, Herzog H, et al. Decreased prefrontal 5-HT_{2A} receptor binding in subjects at enhanced risk for schizophrenia. *Anatomy and Embryology*. 2005;210(5-6):519-23.
113. Klein A, Rosch F, Coenen H, Qaim S. Labelling of manganese-based magnetic resonance imaging (MRI) contrast agents with the positron emitter (51)Mn, as exemplified by manganese-tetraphenyl-porphin-sulfonate (MnTPPS(4)). *Applied Radiation and Isotopes*. 2005;62(5):711-20.
114. Kuhn J, Hofmann B, Knitelius H, Coenen H, Bewermeyer H. Bilateral subdural haematomata and lumbar pseudomeningocele due to a chronic leakage of liquor cerebrospinalis after a lumbar discectomy with the application of ADCON-L gel. *Journal of Neurology Neurosurgery and Psychiatry*. 2005;76(7):1031-3.
115. Langen K, Hamacher K, Bauer D, Broer S, Pauleit D, Herzog H, et al. Preferred stereoselective transport of the D-isomer of cis-4-[F-18]fluoro-proline at the blood-brain barrier. *Journal of Cerebral Blood Flow and Metabolism*. 2005;25(5):607-16.
116. Langen K, Hamacher K, Pauleit D, Floeth F, Stoffels G, Bauer D, et al. Evaluation of new (18)F-labeled amino acids for brain PET. *Anatomy and Embryology*. 2005;210(5-6):455-61.
117. Meyer P, Elmenhorst D, Bier D, Holschbach M, Matusch A, Coenen H, et al. Quantification of cerebral

- A(1) adenosine receptors in humans using [F-18]CPFPX and PET: an equilibrium approach. *Neuroimage*. 2005;24(4):1192-204.
118. Pauleit D, Floeth F, Hamacher K, Riemenschneider M, Reifenberger G, Muller H, et al. O-(2-[F-18]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. *Brain*. 2005;128:678-87.
 119. Pauleit D, Stoffels G, Schaden W, Hamacher K, Bauer D, Tellmann L, et al. PET with O-(2-(18)F-fluoroethyl)-L-tyrosine in peripheral tumors: First clinical results. *Journal of Nuclear Medicine*. 2005;46(3):411-6.
 120. Spahn I, Takacs S, Shubin Y, Tarkanyi F, Coenen H, Qaim S. Cross-section measurement of the Tm-169(p,n) reaction for the production of the therapeutic radionuclide Yb-169 and comparison with its reactor-based generation. *Applied Radiation and Isotopes*. 2005;63(2):235-9.
 121. Weckesser M, Langen K, Rickert C, Kloska S, Straeter R, Hamacher K, et al. O-(2-[F-18]fluoroethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. *European Journal of Nuclear Medicine and Molecular Imaging*. 2005;32(4):422-9.
 122. Blum T, Ermert J, Wutz W, Bier D, Coenen H. First no-carrier-added radioselenation of an adenosine-A(1) receptor ligand. *Journal of Labelled Compounds & Radiopharmaceuticals*. 2004;47(7):415-27.
 123. Coenen H, Eckelman W. In memoriam Gerhard L. Stocklin. *Radiochimica Acta*. 2004;92(4-6):189-91.
 124. Ermert J, Hocke C, Ludwig T, Gail R, Coenen H. Comparison of pathways to the versatile synthon of no-carrier-added 1-bromo-4-[F-18]fluorobenzene. *Journal of Labelled Compounds & Radiopharmaceuticals*. 2004;47(7):429-41.
 125. Gagel B, Reinartz P, DiMartino E, Zimny M, Pinkawa M, Maneschi P, et al. pO(2) polarography versus positron emission tomography [F-18] fluoromisonidazole, [F-18]-2-fluoro-2'-deoxyglucose) - An appraisal of radiotherapeutically relevant hypoxia. *Strahlentherapie Und Onkologie*. 2004;180(10):616-22.
 126. Hassan H, Qaim S, Shubin Y, Azzam A, Morsy M, Coenen H. Experimental studies and nuclear model calculations on proton-induced reactions on Se-nat, Se-76 and Se-77 with particular reference to the production of the medically interesting radionuclides Br-76 and Br-77. *Applied Radiation and Isotopes*. 2004;60(6):899-909.
 127. Kettern K, Shubin Y, Steyn G, van der Walt T, Coenen H, Qaim S. Formation of short-lived positron emitters in reactions of protons of energies up to 200 MeV with the target elements carbon, nitrogen and oxygen. *Applied Radiation and Isotopes*. 2004;60(6):939-45.
 128. Langen K, Jarosch M, Hamacher K, Muhlensiepen H, Weber F, Floeth F, et al. Imaging of gliomas with Cis-4-[F-18]fluoro-L-proline. *Nuclear Medicine and Biology*. 2004;31(1):67-75.
 129. Meyer P, Bier D, Holschbach M, Boy C, Olsson R, Coenen H, et al. Quantification of cerebral A(1) adenosine receptors in humans using [F-18]CPFPX and PET. *Journal of Cerebral Blood Flow and Metabolism*. 2004;24(3):323-33.

130. Pauleit D, Floeth F, Tellmann L, Hamacher K, Hautzel H, Muller H, et al. Comparison of O-(2-(18)F-fluoroethyl)-L-tyrosine PET and 3-(123)I-iodo-alpha-methyl-L-tyrosine SPECT in brain tumors. *Journal of Nuclear Medicine*. 2004;45(3):374-81.
131. Scholten B, Takacs S, Tarkanyi F, Coenen H, Qaim S. Excitation functions of deuteron induced nuclear reactions on enriched Kr-78 with particular relevance to the production of Br-76. *Radiochimica Acta*. 2004;92(4-6):203-7.
132. Sihver W, Bier D, Holschbach M, Schulze A, Wutz W, Olsson R, et al. Binding of tritiated and radioiodinated ZM241,385 to brain A(2A) adenosine receptors. *Nuclear Medicine and Biology*. 2004;31(2):173-7.
133. Spahn I, Coenen H, Qaim S. Enhanced production possibility of the therapeutic radionuclides Cu-64, Cu-67 and Sr-89 via (n,p) reactions induced by fast spectral neutrons. *Radiochimica Acta*. 2004;92(3):183-6.
134. Stoll T, Ermert J, Oya S, Kung H, Coenen H. Application of n.c.a. 4-[F-18] fluorophenol in diaryl ether syntheses of 2-(4-[F-18] fluorophenoxy)-benzylamines. *Journal of Labelled Compounds & Radiopharmaceuticals*. 2004;47(7):443-55.
135. Bauer A, Holschbach M, Cremer M, Weber S, Boy C, Shah N, et al. Evaluation of (18)F-CPFPX, a novel adenosine A(1) receptor ligand: In vitro autoradiography and high-resolution small animal PET. *Journal of Nuclear Medicine*. 2003;44(10):1682-9.
136. Bauer A, Holschbach M, Meyer P, Boy C, Herzog H, Olsson R, et al. In vivo imaging of adenosine A(1) receptors in the human brain with [F-18]CPFPX and positron emission tomography. *Neuroimage*. 2003;19(4):1760-9.
137. Blum T, Ermert J, Coenen H. No-carrier-added synthesis of aliphatic and aromatic radioselenoethers via selenocyanates. *Nuclear Medicine and Biology*. 2003;30(4):361-7.
138. Hilgers K, Stoll T, Skakun Y, Coenen H, Qaim S. Cross-section measurements of the nuclear reactions Zn-nat(d,x)Cu-64, Zn-66(d,alpha)Cu-64 and Zn-68(p,alpha n)Cu-64 for production of Cu-64 and technical developments for small-scale production of Cu-67 via the Zn-70(p,alpha)Cu-64 process. *Applied Radiation and Isotopes*. 2003;59(5-6):343-51.
139. Holschbach M, Wutz W, Schuller M, Bier D, Coenen H. Tritium-labelled 8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine ([H-3]CPFPX), a potent and selective antagonist for the A(1) adenosine receptor. *Journal of Labelled Compounds & Radiopharmaceuticals*. 2003;46(4):365-72.
140. Jones H, Boobis A, Hamacher K, Coenen H, Clark J. PET imaging of pulmonary fibrosis. *Journal of Nuclear Medicine*. 2003;44(3):483-4.
141. Kovacs Z, Scholten B, Tarkanyi F, Coenen H, Qaim S. Cross section measurements using gas and solid targets for production of the positron-emitting radionuclide O-14. *Radiochimica Acta*. 2003;91(4):185-9.
142. Langen K, Jarosch M, Muhlensiepen H, Hamacher K, Broer S, Jansen P, et al. Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. *Nuclear Medicine and Biology*. 2003;30(5):501-8.

143. Larisch R, Klimke A, Hamacher K, Henning U, Estaji S, Hohlfeld T, et al. Influence of synaptic serotonin level on [F-18]altanserin binding to 5HT(2) receptors in man. *Behavioural Brain Research*. 2003;139(1-2):21-9.
144. Pauleit D, Floeth F, Herzog H, Hamacher K, Tellmann L, Muller H, et al. Whole-body distribution and dosimetry of O-(2-[(18F)fluoroethyl]-L-tyrosine. *European Journal of Nuclear Medicine and Molecular Imaging*. 2003;30(4):519-24.
145. Qaim S, Hohn A, Bastian T, El-Azoney K, Blessing G, Spellerberg S, et al. Some optimisation studies relevant to the production of high-purity I-124 and I-120g at a small-sized cyclotron. *Applied Radiation and Isotopes*. 2003;58(1):69-78.
146. Rossouw D, Coenen H. Radiosynthesis and in vitro stability evaluation of various radioiodine-labelled beta-iodoalkylether prosthetic groups linked to model compounds. *Nuclear Medicine and Biology*. 2003;30(4):373-80.
147. Sihver W, Holschbach M, Bier D, Wutz W, Schulze A, Olsson R, et al. Evaluation of radioiodinated 8-cyclopentyl-3-[(E)-3-iodoprop-2-en-1-yl]-1-propylxanthine ([*I]CPIPX) as a new potential A(1) adenosine receptor antagonist for SPECT. *Nuclear Medicine and Biology*. 2003;30(6):661-8.
148. Voges J, Reszka R, Gossmann A, Dittmar C, Richter R, Garlip G, et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. *Annals of Neurology*. 2003;54(4):479-87.
149. Blum T, Ermert J, Coenen H. No-carrier-added (n.c.a.) synthesis of asymmetric [Se-73,Se-75]selenoethers with isonitriles. *Applied Radiation and Isotopes*. 2002;57(1):51-6.
150. Boy C, Holschbach M, Herzog H, Bauer A, Coenen H, Zilles K. Preoperative studies in epilepsy surgery: Analysis of GABA and adenosine receptors in pharmacoresistant focal temporal epilepsy via positron emission tomography (PET). *Klinische Neurophysiologie*. 2002;32(3):147-55.
151. Forutan F, Estalji S, Beu M, Nikolaus S, Hamacher K, Coenen H, et al. Distribution of 5HT(2A) receptors in the human brain: Comparison of data in vivo and post mortem. *Nuklearmedizin-Nuclear Medicine*. 2002;41(4):197-201.
152. Hamacher K, Coenen H. Efficient routine production of the F-18-labelled amino acid O-(2-[F-18]fluoroethyl)-L-tyrosine. *Applied Radiation and Isotopes*. 2002;57(6):853-6.
153. Hamacher K, Hirschfelder T, Coenen H. Electrochemical cell for separation of [F-18]fluoride from irradiated O-18-water and subsequent no carrier added nucleophilic fluorination. *Applied Radiation and Isotopes*. 2002;56(3):519-23.
154. Hautzel H, Muller-Mattheis V, Herzog H, Roden W, Coenen H, Ackermann R, et al. [C-11]acetate positron emission tomography in prostate carcinoma - New perspectives in metabolic imaging. *Urologe a*. 2002;41(6):569-76.
155. Herzog H, Tellmann L, Qaim S, Spellerberg S, Schmid A, Coenen H. PET quantitation and imaging of the non-pure positronemitting iodine isotope I-124. *Applied Radiation and Isotopes*. 2002;56(5):673-9.
156. Hess E, Sichler S, Kluge A, Coenen H. Synthesis of 2-[F-18]fluoro-L-tyrosine via regiospecific fluoro-

de-stannylation. *Applied Radiation and Isotopes*. 2002;57(2):185-91.

157. Holschbach M, Olsson R, Bier D, Wutz W, Sihver W, Schuller M, et al. Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[F-18]fluoropropyl)-1-propylxanthine ([F-18]CPFPX): A potent and selective A(1)-adenosine receptor antagonist for in vivo imaging. *Journal of Medicinal Chemistry*. 2002;45(23):5150-6.
158. Jelinski M, Hamacher K, Coenen H. C-Terminal F-18-fluoroethylamidation exemplified on [Gly-OH9] oxytocin. *Journal of Labelled Compounds & Radiopharmaceuticals*. 2002;45(3):217-29.
159. Kastleiner S, Qaim S, Nortier F, Blessing G, van der Walt T, Coenen H. Excitation functions of Rb-85(p,xn)Sr-85m,Sr-85g,Sr-83,Sr-82,Sr-81 reactions up to 100 MeV: integral tests of cross section data, comparison of production routes of Sr-83 and thick target yield of Sr-82. *Applied Radiation and Isotopes*. 2002;56(5):685-95.
160. Ketterer K, Linse K, Spellerberg S, Coenen H, Qaim S. Radiochemical studies relevant to the production of Y-86 and Y-88 at a small-sized cyclotron. *Radiochimica Acta*. 2002;90(12):845-9.
161. Klein A, Rosch F, Coenen H, Qaim S. Production of the positron emitter Mn-51 via the Cr-50(d, n) reaction: targetry and separation of no-carrier-added radiomanganese. *Radiochimica Acta*. 2002;90(3):167-77.
162. Langen K, Muhlensiepen H, Schmieder S, Hamacher K, Broer S, Borner A, et al. Transport of cis- and trans-4-[F-18]fluoro-L-proline in F98 glioma cells. *Nuclear Medicine and Biology*. 2002;29(6):685-92.
163. Langen K, Pauleit D, Coenen H. 3-[I-123]iodo-alpha-methyl-L-tyrosine: uptake mechanisms and clinical applications. *Nuclear Medicine and Biology*. 2002;29(6):625-31.
164. Ludwig T, Ermert J, Coenen H. 4-[F-18]Fluoroarylethers via an improved synthesis of n.c.a. 4-[F-18]fluorophenol. *Nuclear Medicine and Biology*. 2002;29(2):255-62.
165. Messing-Junger A, Floeth F, Pauleit D, Reifenberger G, Willing R, Gartner J, et al. Multimodal target point assessment for stereotactic biopsy with diffuse bithalamic in children astrocytomas. *Childs Nervous System*. 2002;18(8):445-9.
166. Pissarek M, Ermert J, Oesterreich G, Bier D, Coenen H. Relative uptake, metabolism, and beta-receptor binding of (1R,2S)-4-(18)F-fluorometaraminol and (123)I-MIBG in normotensive and spontaneously hypertensive rats. *Journal of Nuclear Medicine*. 2002;43(3):366-73.
167. Speckmann E, Kohling R, Straub H, Wolf P, Ebner A, Tuxhorn I, et al. Perioperative investigations in epilepsy surgery - An introduction. *Klinische Neurophysiologie*. 2002;32(3):144-6.
168. Stoll T, Kastleiner S, Shubin Y, Coenen H, Qaim S. Excitation functions of proton induced reactions on Zn-68 from threshold up to 71 MeV, with specific reference to the production Of Cu-67. *Radiochimica Acta*. 2002;90(6):309-13.
169. Zimny M, Klosterhalfen B, Conze J, Hamacher K, Fehler S, Schumpelick V, et al. Uptake of cis-4[F-18]fluoro-L-proline in scar formation: a marker of collagen synthesis? *Nuclear Medicine Communications*. 2002;23(7):695-8.

170. Bastian T, Coenen H, Qaim S. Excitation functions of Te-124(d,xn)I-124,I-125 reactions from threshold up to 14 MeV: comparative evaluation of nuclear routes for the production of I-124. *Applied Radiation and Isotopes*. 2001;55(3):303-8.
171. Blum T, Ermert J, Coenen H. Synthesis of asymmetric [Se-75]selenoethers via carbodiimides. *Journal of Labelled Compounds & Radiopharmaceuticals*. 2001;44(8):587-601.
172. Borner A, Langen K, Herzog H, Hamacher K, Muller-Mattheis V, Schmitz T, et al. Whole-body kinetics and dosimetry of cis-4-[F-18]fluoro-L-proline. *Nuclear Medicine and Biology*. 2001;28(3):287-92.
173. Ermert J, Blum T, Hamacher K, Coenen H. Alternative syntheses of [Se-73,Se-75]selenoethers exemplified for homocysteine[Se-73,Se-75]selenolactone. *Radiochimica Acta*. 2001;89(11-12):863-6.
174. Hess E, Takacs S, Scholten B, Tarkanyi F, Coenen H, Qaim S. Excitation function of the O-18(p,n)F-18 nuclear reaction from threshold up to 30 MeV. *Radiochimica Acta*. 2001;89(6):357-62.
175. Hohn A, Nortier F, Scholten B, van der Walt T, Coenen H, Qaim S. Excitation functions of Te-125(p, xn)-reactions from their respective thresholds up to 100 MeV with special reference to the production of I-124. *Applied Radiation and Isotopes*. 2001;55(2):149-56.
176. Langen K, Bonnie R, Muhlensiepen H, Jansen P, Broer S, Holschbach M, et al. 3-[I-123]iodo-alpha-methyl-L-tyrosine transport and 4F2 antigen expression in human glioma cells. *Nuclear Medicine and Biology*. 2001;28(1):5-11.
177. Langen K, Borner A, Muller-Mattheis V, Hamacher K, Herzog H, Ackermann R, et al. Uptake of cis-4-[F-18]fluoro-L-proline in urologic tumors. *Journal of Nuclear Medicine*. 2001;42(5):752-4.
178. Larisch R, Klimke A, Mayoral F, Hamacher K, Herzog H, Vosberg H, et al. Disturbance of serotonin 5HT(2) receptors in remitted patients suffering from hereditary depressive disorder. *Nuklearmedizin-Nuclear Medicine*. 2001;40(4):129-34.
179. Schmidt D, Gottwald U, Langen K, Weber F, Hertel A, Floeth F, et al. 3-[I-123]Iodo-alpha-methyl-L-tyrosine uptake in cerebral gliomas: relationship to histological grading and prognosis. *European Journal of Nuclear Medicine*. 2001;28(7):855-61.
180. Ermert J, Hamacher K, Coenen H. NCA F-18-labelled norephedrine derivatives via alpha-aminopropiophenones. *Journal of Labelled Compounds & Radiopharmaceuticals*. 2000;43(14):1345-63.
181. Hess E, Blessing G, Coenen H, Qaim S. Improved target system for production of high purity [F-18]fluorine via the O-18(p,n)F-18 reaction. *Applied Radiation and Isotopes*. 2000;52(6):1431-40.
182. Hohn A, Coenen H, Qaim S. Excitation functions of Te-120(d,xn)I-121,I-120m,I-g reactions from threshold up to 13.5 MeV: comparative studies on the production of I-120g. *Applied Radiation and Isotopes*. 2000;52(4):923-5.
183. Hohn A, Coenen H, Qaim S. Positron emission intensity in the decay of I-120g. *Radiochimica Acta*. 2000;88(3-4):139-41.

184. Langen K, Muhlsiepen H, Holschbach M, Hautzel H, Jansen P, Coenen H. Transport mechanisms of 3-[I-123]Iodo-alpha-methyl-L-tyrosine in a human glioma cell line: Comparison with [H-3-methyl]-L-methionine. *Journal of Nuclear Medicine*. 2000;41(7):1250-5.
185. Mennicke E, Holschbach M, Coenen H. Direct n.c.a. radioiodination of weakly activated arenes using metal salts. *Radiochimica Acta*. 2000;88(3-4):221-7.
186. Mennicke E, Holschbach M, Coenen H. Direct n.c.a. electrophilic radioiodination of deactivated arenes with N-chlorosuccinimide. *Journal of Labelled Compounds & Radiopharmaceuticals*. 2000;43(7):721-37.
187. Weber S, Bauer A, Herzog H, Kehren F, Muhlsiepen H, Vogelbruch J, et al. Recent results of the TierPET scanner. *Ieee Transactions on Nuclear Science*. 2000;47(4):1665-9.
188. Weckesser M, Schmidt D, Matheja P, Coenen H, Langen K. The role of L-3-I-123-iodine-alpha-methyl tyrosine-SPECT in cerebral gliomas. *Nuklearmedizin-Nuclear Medicine*. 2000;39(8):233-40.
189. Dittmann H, Coenen H, Zolzer F, Dutschka K, Brandau W, Streffer C. In vitro studies on the cellular uptake of melanoma imaging aminoalkyl-iodobenzamide derivatives (ABA). *Nuclear Medicine and Biology*. 1999;26(1):51-6.
190. Kastleiner S, Coenen H, Qaim S. Possibility of production of Cu-67 at a small-sized cyclotron via the (p,alpha)-reaction on enriched Zn-70. *Radiochimica Acta*. 1999;84(2):107-10.
191. Muller T, Eising E, Buttner T, Coenen H, Przuntek H. Delayed motor response correlates with striatal degeneration in Parkinson's disease. *Acta Neurologica Scandinavica*. 1999;100(4):227-30.
192. Schirbel A, Holschbach M, Coenen H. NCA [C-11]CO₂ as a safe substitute for phosgene in the carbonylation of primary amines. *Journal of Labelled Compounds & Radiopharmaceuticals*. 1999;42(6):537-51.
193. Weber S, Herzog H, Cremer M, Engels R, Hamacher K, Kehren F, et al. Evaluation of the TierPET system. *Ieee Transactions on Nuclear Science*. 1999;46(4):1177-83.
194. Hohn A, Coenen H, Qaim S. Nuclear data relevant to the production of (120g)I via the (120)Te(p,n)-process at a small-sized cyclotron. *Applied Radiation and Isotopes*. 1998;49(12):1493-6.
195. Hohn A, Scholten B, Coenen H, Qaim S. Excitation functions of (p,xn) reactions on highly enriched (122)Te: Relevance to the production of (120g)I. *Applied Radiation and Isotopes*. 1998;49(1-2):93-8.
196. Kruger K, Jochum C, Glusenkamp K, Krusemann C, Lorenz P, Eberle-Adamkiewicz G, et al. New modular delivery system for diagnostic and therapeutic pre-targeting using tautomer-specific monoclonal antibody EM-6-47 and 3-substituted adenines. *International Journal of Cancer*. 1998;77(4):610-9.
197. Langen K, Clauss R, Holschbach M, Muhlsiepen H, Kiwit J, Zilles K, et al. Comparison of iodotyrosines and methionine uptake in a rat glioma model. *Journal of Nuclear Medicine*. 1998;39(9):1596-9.
198. Muller T, Farahati J, Kuhn W, Eising E, Przuntek H, Reiners C, et al. [I-123]beta-CIT SPECT visualizes dopamine transporter loss in de novo parkinsonian patients. *European Neurology*. 1998;39(1):44-8.

199. Spellerberg S, Reimer P, Blessing G, Coenen H, Qaim S. Production of $(55)\text{Co}$ and $(57)\text{Co}$ via proton induced reactions on highly enriched $(58)\text{Ni}$. *Applied Radiation and Isotopes*. 1998;49(12):1519-22.
200. Szucs Z, Hamkens W, Takacs S, Tarkanyi F, Coenen H, Qaim S. Excitation functions of N-14(d,t)N-13 and $\text{N-14(d,\alpha n)C-11}$ reactions from threshold to 12.3 MeV: Radionuclidic purity of O-15 produced via the N-14(d,n)O-15 reaction. *Radiochimica Acta*. 1998;80(2):59-63.
201. Eising E, Muller T, Zander C, Kuhn W, Farahati J, Reiners C, et al. SPECT-evaluation of the monoamine uptake site ligand $[\text{I-123}](1\text{R})\text{-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane}$ ($[\text{I-123}]\text{beta-CIT}$) in untreated patients with suspicion of Parkinson disease. *Journal of Investigative Medicine*. 1997;45(8):448-52.
202. Farahati J, Coenen H, Dutschka K, Stuben G, Knuhmann K, Budach W, et al. Effect of specific activity on neuroblastoma uptake of $\text{I-123-meta-iodobenzylguanidine}$ in nude mice xenografted with SK-N-SH cells. *Oncology Reports*. 1997;4(2):363-6.
203. Schmidt D, Langen K, Herzog H, Wirths J, Holschbach M, Kiwit J, et al. Whole-body kinetics and dosimetry of $\text{L-3-[I-123]iodo-alpha-methyltyrosine}$. *European Journal of Nuclear Medicine*. 1997;24(9):1162-6.
204. Brandau W, Niehoff T, Pulawski P, Jonas M, Dutschka K, Sciuk J, et al. Structure distribution relationship of iodine-123-iodobenzamides as tracers for the detection of melanotic melanoma. *Journal of Nuclear Medicine*. 1996;37(11):1865-71.
205. BERGMANN R, BRUST P, KAMPF G, COENEN H, STOCKLIN G. EVALUATION OF RADIOSELENIUM LABELED SELENOMETHIONINE, A POTENTIAL TRACER FOR BRAIN PROTEIN-SYNTHESIS BY PET. *Nuclear Medicine and Biology*. 1995;22(4):475-81.
206. COENEN H, DUTSCHKA K, MULLER S, GEWORSKI L, FARAHATI J, REINERS C. N.C.A. RADIOSYNTHESIS OF $[\text{I-123,I-124}]\text{BETA-CIT}$, PLASMA ANALYSIS AND PHARMACOKINETIC STUDIES WITH SPECT AND PET. *Nuclear Medicine and Biology*. 1995;22(8):977-84.
207. ELMOHTY A, ELKOLALY M, RAIEH M, COENEN H, STOCKLIN G. NO CARRIER ADDED ELECTROPHILIC RADIOIODINATION OF $\text{L-ALPHA-METHYLTYROSINE}$ VIA DIFFERENT OXIDIZING-AGENTS. *Journal of Radioanalytical and Nuclear Chemistry-Articles*. 1995;196(2):303-10.
208. ElMohty A, ElKolaly M, Raieh M, Coenen H, Stocklin G. Radiopharmaceutical preparation of $\text{L-6-[I-123]-iodo-m-tyrosine}$, a potential SPECT brain imaging agent. *Journal of Radioanalytical and Nuclear Chemistry-Articles*. 1995;198(1):215-28.
209. Meyer G, Waters S, Coenen H, Luxen A, Maziere B, Langstrom B. PEI radiopharmaceuticals in Europe: Current use and data relevant for the formulation of summaries of product characteristics (SPCs). *European Journal of Nuclear Medicine*. 1995;22(12):1420-32.
210. REINERS C, BRANDAU W, COENEN H, FISCHER M, SENEKOWITSCH R, SUCHI R. NEWS FROM THE RADIOPHARMACEUTICALS COMMITTEE OF THE GERMAN-SOCIETY-FOR-NUCLEAR-MEDICINE. *Nuklearmedizin*. 1995;34(2):135-6.

211. SCHIRBEL A, COENEN H. COMPARISON OF NONISOTOPIC EXCHANGE METHODS FOR NCA LABELING OF 2-IODOPHENYL-METYRAPONE. *Nuclear Medicine and Biology*. 1995;22(8):1075-9.
212. WEILLER C, MAY A, LIMMROTH V, JUPTNER M, KAUBE H, VONSCHAYCK R, et al. BRAIN-STEM ACTIVATION IN SPONTANEOUS HUMAN MIGRAINE ATTACKS. *Nature Medicine*. 1995;1(7):658-60.
213. EBERT A, HERZOG H, STOCKLIN G, HENRICH M, DEGRADO T, COENEN H, et al. KINETICS OF 14(R,S)-FLUORINE-18-FLUORO-6-THIA-HEPTADECANOIC ACID IN NORMAL HUMAN HEARTS AT REST, DURING EXERCISE AND AFTER DIPYRIDAMOLE INJECTION. *Journal of Nuclear Medicine*. 1994;35(1):51-6.
214. GAIL R, COENEN H. A ONE-STEP PREPARATION OF THE NCA F-18 LABELED SYNTHONS - 4-FLUOROBROMOBENZENE AND 4-FLUOROIODOBENZENE. *Applied Radiation and Isotopes*. 1994;45(1):105-11.
215. GUHLKE S, COENEN H, STOCKLIN G. FLUOROACYLATION AGENTS BASED ON SMALL NCA [F-18] FLUOROCARBOXYLIC ACIDS. *Applied Radiation and Isotopes*. 1994;45(6):715-27.
216. THINIUS O, DUTSCHKA K, COENEN H. REACTIVITY OF IODINE MONOFLUORIDE ON SUBMICROMOLAR SCALE WITH ARENES. *Tetrahedron Letters*. 1994;35(52):9701-2.
217. DEUSSEN A, HENRICH M, HAMACHER K, BORST M, HERZOG H, COENEN H, et al. NONINVASIVE ASSESSMENT OF REGIONAL CARDIAC ADENOSINE USING POSITRON EMISSION TOMOGRAPHY. *Journal of Nuclear Medicine*. 1992;33(12):2138-44.
218. GAIL R, COENEN H, HAMACHER K, STOCKLIN G. C-11 LABELING OF THE ANALGESIC TRAMADOL AND ITS MAJOR METABOLITES BY SELECTIVE O-METHYLATION AND N-METHYLATION. *Applied Radiation and Isotopes*. 1992;43(9):1129-37.
219. MAZIERE B, COENEN H, HALLDIN C, NAGREN K, PIKE V. PET RADIOLIGANDS FOR DOPAMINE-RECEPTORS AND REUPTAKE SITES - CHEMISTRY AND BIOCHEMISTRY. *Nuclear Medicine and Biology*. 1992;19(4):497-512.
220. VAALBURG W, COENEN H, CROUZEL C, ELSINGA P, LANGSTROM B, LEMAIRE C, et al. AMINO-ACIDS FOR THE MEASUREMENT OF PROTEIN-SYNTHESIS INVIVO BY PET. *Nuclear Medicine and Biology*. 1992;19(2):227-37.
221. DEGRADO T, COENEN H, STOCKLIN G. 14(R,S)-[F-18]FLUORO-6-THIA-HEPTADECANOIC ACID (FTHA) - EVALUATION IN MOUSE OF A NEW PROBE OF MYOCARDIAL UTILIZATION OF LONG-CHAIN FATTY-ACIDS. *Journal of Nuclear Medicine*. 1991;32(10):1888-96.
222. JOVKAR S, WIENHARD K, COENEN H, PAWLIK G, HEISS W. QUANTIFICATION OF BABOON CORTICAL S₂ SEROTONIN RECEPTORS INVIVO WITH 3-N-(2'-F18)FLUOROETHYLSPIPERONE AND POSITRON EMISSION TOMOGRAPHY. *European Journal of Nuclear Medicine*. 1991;18(3):158-63.
223. KARBE H, WIENHARD K, HAMACHER K, HUBER M, HERHOLZ K, COENEN H, et al. POSITRON EMISSION TOMOGRAPHY WITH (F-18)METHYLSPIPERONE DEMONSTRATES D₂

- DOPAMINE RECEPTOR-BINDING DIFFERENCES OF CLOZAPINE AND HALOPERIDOL. *Journal of Neural Transmission-General Section*. 1991;86(3):163-73.
224. LANGEN K, ROOSEN N, COENEN H, KUIKKA J, KUWERT T, HERZOG H, et al. BRAIN AND BRAIN-TUMOR UPTAKE OF L-3-[I-123]IODO-ALPHA-METHYL TYROSINE - COMPETITION WITH NATURAL L-AMINO-ACIDS. *Journal of Nuclear Medicine*. 1991;32(6):1225-8.
225. WIENHARD K, HERHOLZ K, COENEN H, RUDOLF J, KLING P, STOCKLIN G, et al. INCREASED AMINO-ACID-TRANSPORT INTO BRAIN-TUMORS MEASURED BY PET OF L-(2-F-18)FLUOROTYROSINE. *Journal of Nuclear Medicine*. 1991;32(7):1338-46.
226. Cox P, Coenen H, Deckart H, Feuger G, Hesslewood S, Kristensen K, et al. REPORT AND RECOMMENDATIONS ON THE REQUIREMENTS FOR POSTGRADUATE TRAINING IN RADIOPHARMACY AND RADIOPHARMACEUTICAL CHEMISTRY 1989. *European Journal of Nuclear Medicine*. 1990;17(5):203-11.
227. FRANKEN K, COENEN H. REACTIONS OF I-125 WITH GASEOUS ETHENE INDUCED VIA EC-DECAY OF XE-125. *Radiochimica Acta*. 1990;50(1-2):97-105.
228. HERZOG H, COENEN H, KUWERT T, LANGEN K, FEINENDEGEN L. QUANTIFICATION OF THE WHOLE-BODY DISTRIBUTION OF PET RADIOPHARMACEUTICALS, APPLIED TO 3-N-([F-18]FLUOROETHYL)SPIPERONE. *European Journal of Nuclear Medicine*. 1990;16(2):77-83.
229. JOVKAR S, WIENHARD K, PAWLIK G, COENEN H. THE QUANTITATIVE-ANALYSIS OF D2-DOPAMINE RECEPTORS IN BABOON STRIATUM INVIVO WITH 3-N-[2'-F-18]FLUOROETHYLSPIPERONE USING POSITRON EMISSION TOMOGRAPHY. *Journal of Cerebral Blood Flow and Metabolism*. 1990;10(5):720-6.
230. LANGEN K, COENEN H, ROOSEN N, KLING P, MUZIK O, HERZOG H, et al. SPECT STUDIES OF BRAIN-TUMORS WITH L-3-[I-123] IODO-ALPHA-METHYL TYROSINE - COMPARISON WITH PET, 124IMT AND 1ST CLINICAL-RESULTS. *Journal of Nuclear Medicine*. 1990;31(3):281-6.
231. VERARUIZ H, MARCUS C, PIKE V, COENEN H, FOWLER J, MEYER G, et al. REPORT OF AN INTERNATIONAL-ATOMIC-ENERGY-AGENCY ADVISORY GROUP MEETING ON QUALITY-CONTROL OF CYCLOTRON-PRODUCED RADIOPHARMACEUTICALS. *Nuclear Medicine and Biology*. 1990;17(5):445-56.
232. WIENHARD K, COENEN H, PAWLIK G, RUDOLF J, LAUFER P, JOVKAR S, et al. PET STUDIES OF DOPAMINE RECEPTOR DISTRIBUTION USING [F-18] FLUOROETHYLSPIPERONE - FINDINGS IN DISORDERS RELATED TO THE DOPAMINERGIC SYSTEM. *Journal of Neural Transmission-General Section*. 1990;81(3):195-213.
233. BIERSACK H, COENEN H, STOCKLIN G, REICHMANN K, BOCKISCH A, OEHR P, et al. IMAGING OF BRAIN-TUMORS WITH L-3-[I-123]IODO-ALPHA-METHYL TYROSINE AND SPECT. *Journal of Nuclear Medicine*. 1989;30(1):110-2.
234. COENEN H, KLING P, STOCKLIN G. CEREBRAL METABOLISM OF L-[2-F-18]FLUOROTYROSINE, A NEW PET TRACER OF PROTEIN-SYNTHESIS. *Journal of Nuclear Medicine*. 1989;30(8):1367-72.

235. RESKE S, BRANDAU W, COENEN H, MEYER G, OSTERTAG H, SCHOBBER O, et al. RADIOPHARMACEUTICALS AND AMG-73. *Nuklearmedizin*. 1989;28(5):208-14.
236. BLOCK D, COENEN H, STOCKLIN G. NCA F-18-FLUOROACYLATION VIA FLUOROCARBOXYLIC ACID-ESTERS. *Journal of Labelled Compounds & Radiopharmaceuticals*. 1988;25(2):185-200.
237. BLOCK D, COENEN H, STOCKLIN G. NCA F-18-FLUOROALKYLATION OF H-ACIDIC COMPOUNDS. *Journal of Labelled Compounds & Radiopharmaceuticals*. 1988;25(2):201-16.
238. BODSCH W, COENEN H, STOCKLIN G, TAKAHASHI K, HOSSMANN K. BIOCHEMICAL AND AUTORADIOGRAPHIC STUDY OF CEREBRAL PROTEIN-SYNTHESIS WITH [F-18]FLUOROPHENYLALANINE AND [C-14]FLUOROPHENYLALANINE. *Journal of Neurochemistry*. 1988;50(3):979-83.
239. COENEN H, FRANKEN K, KLING P, STOCKLIN G. DIRECT ELECTROPHILIC RADIOFLUORINATION OF PHENYLALANINE, TYROSINE AND DOPA. *Applied Radiation and Isotopes*. 1988;39(12):1243-50.
240. COENEN H, WIENHARD K, STOCKLIN G, LAUFER P, I H, PAWLIK G, et al. PET MEASUREMENT OF D2 AND S2 RECEPTOR-BINDING OF 3-N-([2-F-18]FLUOROETHYL)SPIPERONE IN BABOON BRAIN. *European Journal of Nuclear Medicine*. 1988;14(2):80-7.
241. HANKES L, COENEN H, ROTA E, LANGEN K, HERZOG H, STOECKLIN G, et al. BLOOD-BRAIN BARRIER BLOCKS TRANSPORT OF CARBOXYL-C-11-NICOTINIC ACID INTO HUMAN-BRAIN. *European Journal of Nuclear Medicine*. 1988;14(1):53-4.
242. BLOCK D, COENEN H, STOCKLIN G. THE NCA NUCLEOPHILIC F-18 FLUORINATION OF 1,N-DISUBSTITUTED ALKANES AS FLUOROALKYLATION AGENTS. *Journal of Labelled Compounds & Radiopharmaceuticals*. 1987;24(9):1029-42.
243. COENEN H, MOERLEIN S. REGIOSPECIFIC AROMATIC FLUORODEMETALLATION OF GROUP-IVB METALLOARENES USING ELEMENTAL FLUORINE OR ACETYL HYPOFLUORITE. *Journal of Fluorine Chemistry*. 1987;36(1):63-75.
244. COENEN H, PIKE V, STOCKLIN G, WAGNER R. RECOMMENDATION FOR A PRACTICAL PRODUCTION OF [2-F-18]FLUORO-2-DEOXY-D-GLUCOSE. *Applied Radiation and Isotopes*. 1987;38(8):605-10.
245. CROUZEL C, LANGSTROM B, PIKE V, COENEN H. RECOMMENDATIONS FOR A PRACTICAL PRODUCTION OF [C-11] METHYL-IODIDE. *Applied Radiation and Isotopes*. 1987;38(8):601-3.
246. METWALLY S, COENEN H, STOCKLIN G. PROTECTION OF FUNCTIONAL-GROUPS AND STANNYLATION OF PHENYLALANINE. *Bulletin of the Chemical Society of Japan*. 1987;60(12):4437-40.
247. BLESSING G, COENEN H, FRANKEN K, QAIM S. PRODUCTION OF [F-18] F2, HF(F-18) AND F-

18(AQ)- USING THE NE-20(D, ALPHA)F-18 PROCESS. Applied Radiation and Isotopes. 1986;37(11):1135-9.

248. BLOCK D, COENEN H, LAUFER P, STOCKLIN G. NCA [F-18] FLUOROALKYLATION VIA NUCLEOPHILIC FLUORINATION OF DISUBSTITUTED ALKANES AND APPLICATION TO THE PREPARATION OF N-[F-18]-FLUOROETHYLSPERONE. Journal of Labelled Compounds & Radiopharmaceuticals. 1986;23(10-12):1042-4.
249. COENEN H, COLOSIMO M, SCHULLER M, STOCKLIN G. PREPARATION OF NCA [F-18] CH₂BRF VIA AMINOPOLYETHER SUPPORTED NUCLEOPHILIC-SUBSTITUTION. Journal of Labelled Compounds & Radiopharmaceuticals. 1986;23(6):587-95.
250. COENEN H, FRANKEN K, METWALLY S, STOCKLIN G. ELECTROPHILIC RADIOFLUORINATION OF AROMATIC-COMPOUNDS WITH [F-18] F₂ AND [F-18] CH₃CO₂F AND REGIOSELECTIVE PREPARATION OF L-P-[F-18]-FLUOROPHENYLALANINE. Journal of Labelled Compounds & Radiopharmaceuticals. 1986;23(10-12):1179-81.
251. COENEN H, KLATTE B, KNOCHEL A, SCHULLER M, STOCKLIN G. PREPARATION OF NCA [17-F-18]-FLUOROHEPTADECANOIC ACID IN HIGH YIELDS VIA AMINOPOLYETHER SUPPORTED, NUCLEOPHILIC FLUORINATION. Journal of Labelled Compounds & Radiopharmaceuticals. 1986;23(5):455-66.
252. HAMACHER K, COENEN H, STOCKLIN G. EFFICIENT STEREOSPECIFIC SYNTHESIS OF NO-CARRIER-ADDED 2-[F-18]-FLUORO-2-DEOXY-D-GLUCOSE USING AMINOPOLYETHER SUPPORTED NUCLEOPHILIC-SUBSTITUTION. Journal of Nuclear Medicine. 1986;27(2):235-8.
253. MOERLEIN S, COENEN H. REGIOSPECIFIC NO-CARRIER-ADDED RADIOBROMINATION AND RADIOIODINATION OF ARYLTRIMETHYL GROUP IVB ORGANOMETALLICS. Journal of the Chemical Society-Perkin Transactions 1. 1985(9):1941-7.